2024 Best of JAMA Dermatology

Kanade Shankai from JAMA Dermatology highlights recent advancements in dermatological practice and ongoing studies that aim to enhance patient care. Key findings include the efficacy of arinumab for treating rosacea, particularly for patients with severe flushing, and oral minoxidil's comparative effectiveness for androgenetic alopecia, revealing it's not superior to the topical version but has its own side effects. A modified Delphi study on minoxidil usage established consensus among experts on various treatment aspects. New insights were also provided on alopecia areata, illustrating that stopping baricitinib leads to eventual disease recurrence, signaling the need for continued treatment. The LIGHT trial indicated that home-based UVB therapy for psoriasis yields similar outcomes as office treatment but with better adherence. A patient-consensus study on defining "flare" in atopic dermatitis opened a dialogue about better patient-reported outcome measures. A cohort study revealed notable nail abnormalities in patients with BAP1 syndrome, emphasizing the need for thorough skin examinations. Concerns regarding the regulation of dermatology-related mobile apps, which lack FDA approval and transparency, were raised. Additionally, the economic evaluation of biologics for psoriasis highlighted the significant variability in drug pricing. Recruitment strategies for clinical trials have been refined to enhance diversity, such as utilizing cross-polarized photography, and the impact of processing methods on benzene levels in topical products continues to be investigated. This summary resonates with JAMA Dermatology's commitment to improving dermatological outcomes and fostering informed discussions.